193 related articles for article (PubMed ID: 16146690)
1. Molecular prognostic markers in pancreatic cancer: a systematic review.
Garcea G; Neal CP; Pattenden CJ; Steward WP; Berry DP
Eur J Cancer; 2005 Oct; 41(15):2213-36. PubMed ID: 16146690
[TBL] [Abstract][Full Text] [Related]
2. Molecular prognostic markers in pancreatic cancer.
Ghaneh P; Kawesha A; Evans JD; Neoptolemos JP
J Hepatobiliary Pancreat Surg; 2002; 9(1):1-11. PubMed ID: 12021893
[TBL] [Abstract][Full Text] [Related]
3. [Tumour markers of pancreatic cancer--Part II (molecular markers of carcinogenesis and non-specific tumour markers)].
Groblewska M; Mroczko B; Karpiuk E; Szmitkowski M
Pol Arch Med Wewn; 2005 Nov; 114(5):1118-27. PubMed ID: 16789513
[No Abstract] [Full Text] [Related]
4. Prognostic significance of molecular alterations in human pancreatic carcinoma--an immunohistological study.
Gansauge F; Gansauge S; Schmidt E; Müller J; Beger HG
Langenbecks Arch Surg; 1998 Apr; 383(2):152-5. PubMed ID: 9641888
[TBL] [Abstract][Full Text] [Related]
5. Molecular oncology in pancreatic cancer.
Gansauge S; Gansauge F; Beger HG
J Mol Med (Berl); 1996 Jun; 74(6):313-20. PubMed ID: 8862512
[TBL] [Abstract][Full Text] [Related]
6. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer.
Qin R; Smyrk TC; Reed NR; Schmidt RL; Schnelldorfer T; Chari ST; Petersen GM; Tang AH
Br J Cancer; 2015 Feb; 112(3):514-22. PubMed ID: 25584484
[TBL] [Abstract][Full Text] [Related]
7. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
[TBL] [Abstract][Full Text] [Related]
8. Role of tumour markers, cytogenetics.
Lamerz R
Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
[TBL] [Abstract][Full Text] [Related]
9. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.
Sakorafas GH; Tsiotou AG; Tsiotos GG
Cancer Treat Rev; 2000 Feb; 26(1):29-52. PubMed ID: 10660490
[TBL] [Abstract][Full Text] [Related]
10. [Recent advances in gene change of pancreatic cancer].
Wang YY; Cui QC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):79-82. PubMed ID: 15052782
[TBL] [Abstract][Full Text] [Related]
11. Molecular prognostic markers in resectable colorectal liver metastases: a systematic review.
Neal CP; Garcea G; Doucas H; Manson MM; Sutton CD; Dennison AR; Berry DP
Eur J Cancer; 2006 Aug; 42(12):1728-43. PubMed ID: 16815701
[TBL] [Abstract][Full Text] [Related]
12. [New molecular targets in pancreatic cancer].
Torrisani J; Bournet B; Cordelier P; Buscail L
Bull Cancer; 2008 May; 95(5):503-12. PubMed ID: 18541514
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection.
Niedergethmann M; Hildenbrand R; Wolf G; Verbeke CS; Richter A; Post S
Int J Pancreatol; 2000 Aug; 28(1):31-9. PubMed ID: 11185708
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer.
Ansari D; Rosendahl A; Elebro J; Andersson R
Br J Surg; 2011 Aug; 98(8):1041-55. PubMed ID: 21644238
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathology of pancreatic cancer.
Hruban RH; Iacobuzio-Donahue C; Wilentz RE; Goggins M; Kern SE
Cancer J; 2001; 7(4):251-8. PubMed ID: 11561601
[TBL] [Abstract][Full Text] [Related]
16. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis.
Liu L; Zhi Q; Shen M; Gong FR; Zhou BP; Lian L; Shen B; Chen K; Duan W; Wu MY; Tao M; Li W
Oncotarget; 2016 Jul; 7(30):47145-47162. PubMed ID: 27323403
[TBL] [Abstract][Full Text] [Related]
17. Molecular prognostic markers in pancreatic cancer.
Coppola D
Cancer Control; 2000; 7(5):421-7. PubMed ID: 11000611
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia and angiogenesis in pancreatic cancer.
Garcea G; Doucas H; Steward WP; Dennison AR; Berry DP
ANZ J Surg; 2006 Sep; 76(9):830-42. PubMed ID: 16922908
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1, p16(INK) (4A) and p27(Kip1) in pancreatic adenocarcinoma: assessing prognostic implications through quantitative image analysis.
Georgiadou D; Sergentanis TN; Sakellariou S; Filippakis GM; Zagouri F; Vlachodimitropoulos D; Psaltopoulou T; Lazaris AC; Patsouris E; Zografos GC
APMIS; 2014 Dec; 122(12):1230-9. PubMed ID: 25053516
[TBL] [Abstract][Full Text] [Related]
20. Expression of Matrix Metalloproteinases-2/-9 is Associated With Microvessel Density in Pancreatic Cancer.
Xiang T; Xia X; Yan W
Am J Ther; 2017; 24(4):e431-e434. PubMed ID: 26866436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
